What Does Progesterone Do? Sleep, Anxiety, Mood & More

Progesterone is usually described as the hormone that prepares the uterus for pregnancy. In menopause care, it's often treated as an add-on whose only job is to protect the uterine lining when a woman takes estrogen.

That undersells it. Progesterone receptors sit in the brain, bone, breast, blood vessels, airways, and immune cells. One of its breakdown products is among the most potent calming compounds the brain makes.

Progesterone also tends to fall first. You make it mainly after ovulation, and as ovulation becomes less reliable in your late 30s and 40s, progesterone drops, often months to years before estrogen does. That's why the earliest signs of perimenopause are often poor sleep, anxiety, heavier periods, and shorter fuses, not hot flashes.

Here is what the research shows about progesterone, system by system, including where the evidence is strong and where it's still thin.

A note on terms: progesterone here means the hormone your body makes, or micronized progesterone, which is chemically identical. Progestins are synthetic versions such as medroxyprogesterone acetate (MPA). They don't act the same way, and that difference matters in several sections below.

1. Your brain: progesterone becomes a calming neurosteroid

Much of what progesterone does in the brain comes from what it turns into. Part of it is converted to allopregnanolone, a neurosteroid that acts on GABA-A receptors, the same calming system that anti-anxiety medications target. Allopregnanolone makes those receptors respond more strongly to GABA, which quiets the nervous system.

This isn't just theory. A synthetic form of allopregnanolone, brexanolone, is FDA-approved to treat postpartum depression, which is triggered by the sudden crash in progesterone after birth. Its success has reshaped how researchers think about hormone-related mood disorders.

Perimenopause is the newest target. Researchers at Brigham and Women's Hospital have been studying whether allopregnanolone changes drive depression during the menopause transition. A current trial there is testing pregnenolone, a precursor that raises allopregnanolone, in women aged 40 to 60, with results expected in 2027.

More isn't always better

The calming effect follows a curve. At high levels, allopregnanolone is sedating. But a 2025 review on neurosteroids and PMDD, published by Cambridge University Press, notes that in a minority of people, lower levels or rapid changes can cause anxiety and irritability instead. People differ in how their brains respond.

That helps explain why some women feel wonderful on progesterone and others feel flat or irritable. It's not in their heads. It's in their receptors.

2. Sleep: deeper sleep without the usual sleeping-pill tradeoffs

Because of its GABA effect, progesterone has a natural sedating quality. That's why micronized progesterone is usually taken at bedtime.

A 2021 meta-analysis in the Journal of Clinical Endocrinology & Metabolism pooled 9 randomized trials with 388 participants, mostly postmenopausal women. Micronized progesterone helped people fall asleep faster, and most trials found better self-reported sleep. Effects on total sleep time were less consistent.

What stands out from sleep lab studies is how it works. Many sleep medications suppress deep sleep. Progesterone tends to support it, which is the restorative stage that declines with age.

The type matters. A separate meta-analysis from Sichuan University on menopausal hormone therapy and sleep found no general benefit from estrogen alone, while regimens with micronized progesterone or MPA did improve self-reported sleep. Transdermal estrogen also appeared to do better than oral.

If you're waking at 3 a.m. most nights, see Waking at 3 AM, Every Night.

3. Mood: it's not low progesterone, it's sensitivity to the change

The research on progesterone and mood has shifted in an important way. In conditions like PMDD (premenstrual dysphoric disorder), hormone levels are usually normal. What differs is how the brain reacts to them.

In a 2023 brain imaging study in Translational Psychiatry, women with PMDD showed stronger activity in emotion-processing regions during the late luteal phase, the days before a period. That pattern was tied to their levels of allopregnanolone and a related neurosteroid that blocks its effect. Healthy women showed the opposite relationship.

Other evidence points the same way:

In a randomized crossover trial, dutasteride, a drug that blocks progesterone from converting into allopregnanolone, prevented PMDD symptoms.
Sepranolone, an injectable drug designed to counter allopregnanolone at the receptor, is being studied for PMDD.
A Johns Hopkins trial, running through 2029, is measuring neurosteroids and GABA receptor changes across the cycle in 288 women with and without PMDD.

Genetics likely plays a part too. NIH researchers have found that cells from women with PMDD respond differently to the same estrogen and progesterone, and early studies have linked variations in the estrogen receptor gene (ESR1) to PMDD risk. No genetic test can diagnose PMDD yet, but this supports what many women already know: their reaction to hormones is built into their biology, not a matter of willpower.

Why this matters in perimenopause

PMDD, postpartum depression, and perimenopausal depression share one feature: they happen when reproductive hormones swing or drop. Researchers studying perimenopausal depression are building directly on what was learned from postpartum depression and PMDD.

The practical takeaway is that a normal progesterone lab result doesn't rule out a hormonal cause for mood symptoms. Timing, patterns, and personal history tell you more than a single number.

4. Hot flashes and night sweats: progesterone on its own

Hot flash research has focused almost entirely on estrogen, and on women after menopause. Women who are still having periods have been largely left out.

Dr. Jerilynn Prior's group at the University of British Columbia ran the first large trial in this group. Published in Scientific Reports in 2023, it randomized 189 perimenopausal women who had menstruated within the past year to 300 mg of oral micronized progesterone or placebo at bedtime.

The results were mixed but useful:

The main hot flash score did not differ significantly between groups.
Women on progesterone did report a significantly greater drop in night sweats and better sleep quality.
Progesterone did not increase depression.

The investigators agree a larger trial is still needed. But for a woman still cycling who wakes up drenched twice a week or more, it gives a reasonable option to discuss that doesn't involve estrogen.

5. Bone: estrogen slows loss, progesterone helps build

Most people think of estrogen as the bone hormone. It's essential, but it mainly slows bone breakdown. Progesterone appears to work on the other side, helping bone-building cells called osteoblasts form new bone.

The two are meant to work together. A 2010 review by Seifert-Klauss and Prior in the Journal of Osteoporosis pulled the evidence together:

Progesterone stimulates osteoblasts in lab studies.
In a meta-analysis of prospective studies, women with regular periods but silent ovulation problems, such as skipped ovulation or a short luteal phase, lost more spinal bone density. Their periods looked normal, but their progesterone wasn't.
Bone is lost faster in perimenopause than after menopause, and lower progesterone is thought to contribute.
After menopause, progesterone alone didn't prevent bone loss in women with high bone turnover. But combined with estrogen, a progestogen produced greater bone density gains than estrogen alone in several studies.

There's an important gap: no studies yet show progesterone lowers fractures. Still, it's one more reason the perimenopause years matter for bone, well before a DEXA scan shows a problem. More on that in Bone Loss Starts in Perimenopause.

6. Breast: the type of progestogen matters

The Women's Health Initiative used conjugated equine estrogens plus medroxyprogesterone acetate (MPA), a synthetic progestin. The breast cancer increase it found drove fear of all hormone therapy for two decades. But several large studies suggest the progestogen used makes a real difference.

French E3N cohort (54,548 women): Hormone therapy with synthetic progestins was tied to a higher breast cancer risk (relative risk 1.4). Therapy with micronized progesterone was not (relative risk 0.9). This held even when estrogen was given through the skin.
UK case-control study (43,183 cases): Synthetic progestins were associated with higher risk (odds ratio 1.28). Micronized progesterone was not (odds ratio 0.99).
Pooled analysis of 86,881 women: Progesterone was linked to a 33% lower breast cancer risk than synthetic progestins when combined with estrogen.

What we still don't know

These are observational studies, not randomized trials. A systematic review concluded estrogen plus micronized progesterone doesn't raise breast cancer risk for up to about five years, but there's limited evidence the risk may rise with longer use. No randomized trial has tested modern regimens such as transdermal estradiol plus micronized progesterone for breast cancer.

So the fair summary is: micronized progesterone looks meaningfully safer for the breast than synthetic progestins, but "no risk at any duration" isn't proven.

7. Blood clots and blood vessels

Blood clots are one of the most common worries about hormone therapy. The research shows that both the route of estrogen and the type of progestogen shape that risk.

The French ESTHER study, published in Circulation, compared 271 women who'd had a first unexplained blood clot with 610 controls. Its findings:

Oral estrogen raised clot risk. Transdermal estrogen did not.
Micronized progesterone was not associated with higher clot risk.
One class of synthetic progestins, the norpregnane derivatives, was tied to about four times the risk.

A later meta-analysis confirmed that among women using transdermal estrogen, adding micronized progesterone didn't change clot risk.

The pattern is consistent: if clot risk is a concern, transdermal estrogen with micronized progesterone has the most reassuring data.

8. The uterus: still progesterone's non-negotiable job

Estrogen makes the uterine lining grow. Without enough progesterone to balance it, that lining can overgrow, which raises the risk of endometrial cancer. This is why any woman with a uterus who uses systemic estrogen needs a progestogen.

When the FDA removed most of the black box warning on menopausal hormone therapy in November 2025, it deliberately kept one piece: the boxed warning on endometrial cancer for estrogen-only products. That decision reinforces how central this role is.

The same imbalance shows up before menopause too. When ovulation becomes irregular in perimenopause, estrogen can run high while progesterone falls. That's one reason heavy or unpredictable periods are so common in the 40s.

Because protection depends on getting the dose and schedule right, especially over long periods, monitoring matters. Unexpected bleeding on hormone therapy should always be checked.

9. Breathing and sleep apnea

Progesterone stimulates breathing. It makes the brain's breathing center more sensitive to carbon dioxide, which is part of why women breathe more deeply in pregnancy and in the second half of the cycle.

Obstructive sleep apnea becomes much more common in women after menopause. A 2022 PLOS ONE study of 774 women aged 40 to 67 across seven European countries found that women with lower estrogen and progesterone were more likely to snore and report sleep apnea symptoms. Each doubling of progesterone was tied to 9% lower odds of snoring.

Whether hormone therapy actually treats sleep apnea is unclear. A small pilot found estrogen reduced breathing disturbances and adding a progestin reduced them further, but a 15-woman trial found short-term hormone therapy didn't help moderate apnea. Hormones aren't a replacement for a sleep study and CPAP.

The takeaway: new snoring, morning headaches, or unrefreshing sleep in your late 40s deserve an apnea screen, not just a hormone conversation.

What this means for you

Progesterone isn't a side character to estrogen. It's often the first hormone to change, and it reaches your brain, sleep, bones, breasts, blood vessels, and breathing. For the other half of the story, see What Does Estrogen Do in the Body?

A few practical takeaways:

Early perimenopause often looks like a progesterone problem. New anxiety, broken sleep, irritability, and heavier periods in your late 30s or 40s are worth connecting, even if your periods are still regular.
Bioidentical and synthetic are not interchangeable. Micronized progesterone has better breast and blood clot data than most synthetic progestins.
Route and pairing matter. Transdermal estrogen with micronized progesterone has the most reassuring safety data.
Mood reactions are real. If progesterone makes you feel worse, that's a known sensitivity, not a personal failing. Dose, timing, and form can often be adjusted.
One lab value won't tell the whole story. Progesterone shifts across the cycle, and sensitivity matters as much as level.
New snoring or unrefreshing sleep deserves a sleep apnea screen.

Hormone therapy isn't right for every woman, and the best plan depends on your history, symptoms, and goals.

References

Brigham and Women's Hospital. Targeting allopregnanolone to probe behavioral and neurobiological mechanisms that underlie depression in women across the menopause transition. ClinicalTrials.gov NCT06238700. View source
Neurosteroids and premenstrual dysphoric disorder. Cambridge University Press, published online June 16, 2025. View source
Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. J Clin Endocrinol Metab. 2021. View source
Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Commentary by the International Menopause Society. View source
Emotion-induced brain activation across the menstrual cycle in individuals with premenstrual dysphoric disorder and associations to serum levels of progesterone-derived neurosteroids. Transl Psychiatry. 2023;13(1):124. View source
Allopregnanolone in premenstrual dysphoric disorder: evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. View source
Johns Hopkins University. Allopregnanolone and dynamic GABA-A receptor plasticity in SSRI-responsive premenstrual dysphoric disorder. ClinicalTrials.gov NCT06704594. View source
Huo L, Straub RE, Roca C, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry. 2007;62(8):925–933. View source
Dubey N, Hoffman JF, Schuebel K, et al. The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Mol Psychiatry. 2017. View source
Prior JC, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a Phase III Canada-wide randomized placebo-controlled 4-month trial. Sci Rep. 2023;13:9082. View source
Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010;2010:845180. View source
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005. View source
Menopausal hormone therapy formulation and breast cancer risk, UK Clinical Practice Research Datalink case-control study. Summary in Physician's Weekly. View source
Asi N, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016. View source
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. View source
Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric. 2018. View source
Elimination of the black box warning on menopausal hormone therapy. Obstet Gynecol. 2026;147(5):642–646. View source
Triebner K, et al. Female sex hormones and symptoms of obstructive sleep apnea in European women of a population-based cohort. PLOS ONE. 2022. View source
Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. Menopause. 1999;6(3):196–200. View source
Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax. View source